共 50 条
- [1] A FIRST-IN-HUMAN PHASE I STUDY OF M6223 (TIGIT INHIBITOR) AS MONOTHERAPY OR IN COMBINATION WITH BINTRAFUSP ALFA IN PATIENTS WITH METASTATIC OR LOCALLY ADVANCED SOLID UNRESECTABLE TUMORSJOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A561 - A561Watson, GeoffreyMcKean, MeredithTolcher, AnthonyVictor, AnjaZhang, SenPierre, VadrynRichter, EmiliaNaing, AungNaing, Aung
- [2] TIGIT inhibitor M6223 as monotherapy or in combination with bintrafusp alfa in patients with advanced solid tumors: a first-in-human, phase 1, dose-escalation trialJOURNAL FOR IMMUNOTHERAPY OF CANCER, 2025, 13 (02)Naing, AungMckean, MeredithTolcher, AnthonyVictor, AnjaHu, PingGao, WeiFilho, Marco A. F. NogueiraKitzing, ThomasGleicher, StephanHolland, DanielRichter, EmiliaTadjalli-Mehr, KeyvanSiu, Lillian L.
- [3] Phase I study of TIGIT inhibitor M6223 as monotherapy or in combination with bintrafusp alfa (BA) in patients (pts) with metastatic/locally advanced solid unresectable tumoursANNALS OF ONCOLOGY, 2022, 33 (07) : S887 - S887Siu, L. L.Mckean, M. A.Tolcher, A. W.Victor, A.Kitzing, T.Pierre, V.Gleicher, S.Holland, D. G.Richter, E.Naing, A.
- [4] First-in-human phase I trial of SRF617, a potent inhibitor of CD39 activity, as monotherapy or in combination, in patients (pts) with advanced solid tumorsANNALS OF ONCOLOGY, 2021, 32 : S1435 - S1436Patnaik, A.Mehmi, I.Strauss, J.Xing, Y.Jamal, R.O'Neill, A.Lake, A. C.Koseoglu, S.Warren, M. C.Chung, J-K.Alika, A.Lis, R.Rasco, D.Salawu, A. T.Chow, W.Spreafico, A.
- [5] First-in-human study of ATR inhibitor IMP9064 monotherapy and in combination with PARP inhibitor senaparib in patients with advanced solid tumorsANNALS OF ONCOLOGY, 2023, 34 : S476 - S477Lin, C-C.Schneider, R. E.Gutierrez, M.Shen, L.Gao, B.Chung, K.Doroshow, D. B.Millward, M.Hsieh, C-Y.Xu, C.Cai, S. X.Tian, Y. E.Liu, L.Shen, C.Li, B.Tan, Y.Zhang, C.Li, L.Ma, M.Chen, X.
- [6] First-in-human study of ABBV-514 as monotherapy and in combination with budigalimab in patients with advanced solid tumorsANNALS OF ONCOLOGY, 2023, 34 : S647 - S648Babu, S.Kondo, S.Ammakkanavar, N.Spira, A. I.Perets, R.Doi, T.Bar, J.Vandross, A.Sommerhalder, D.Nikolic, V.Tribouley, C.Atluri, H.Hong, J.Paustian, A.Leibman, R.Powderly, J.
- [7] Nemvaleukin alfa monotherapy and in combination with pembrolizumab in patients (pts) with advanced solid tumors: ARTISTRY-1JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)Vaishampayan, Ulka N.Tomczak, PiotrMuzaffar, JameelWiner, Ira SethRosen, Seth DavidHoimes, Christopher J.Chauhan, AmanSpreafico, AnnaLewis, Karl D.Bruno, Debora S.Dumas, OlivierMcDermott, David F.Strauss, James FredricChu, Quincy S.Gilbert, LucyChaudhry, ArvindGraham, Julie R.Boni, ValentinaErnstoff, Marc S.Velcheti, Vamsidhar
- [8] First-in-human study of AMG 208, an oral MET inhibitor, in adult patients (pts) with advanced solid tumorsJOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)Hong, David S.Rosen, Peter J.Lockhart, A. CraigFu, SiqingJanku, FilipKurzrock, RazelleKhan, RabiaAmore, BennyCaudillo, IsaacDeng, HongjieHwang, Yuying C.Loberg, Robert D.Shubhakar, PoornimaZoog, StephenBeaupre, Darrin M.Lee, Peter
- [9] ARTISTRY-1: Nemvaleukin alfa monotherapy and in combination with pembrolizumab in patients (pts) with advanced solid tumors.JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)Boni, ValentinaWiner, Ira SethGilbert, LucyVaishampayan, Ulka N.Rosen, Seth DavidMuzaffar, JameelSpreafico, AnnaMcDermott, David F.Chu, Quincy S.Dumas, OlivierChauhan, AmanChaudhry, ArvindTomczak, PiotrBruno, Debora S.Du, YangchunBidollari, IldaRege, Jessicca MartinErnstoff, Marc S.Strauss, James F.Velcheti, Vamsidhar
- [10] Phase I, first-in-human trial of an oral VEGFR tyrosine kinase inhibitor (TKI) x-82 in patients (pts) with advanced solid tumorsJOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)Moore, Kathleen N.Jones, Suzanne FieldsKurkjian, CarlaArkenau, Hendrik-TobiasInfante, Jeffrey R.Pant, ShubhamBurris, Howard A.McMeekin, D. ScottGibbons, JayHarrow, KimberlyLiang, ChrisRamsey, SaraBendell, Johanna C.